Q2 2025 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated top line growth of 12.3% year-over-year, reaching INR1,988 crore in Q2 FY2025.
- The hospital business revenues increased by 13.9% to INR1,655 crore, with an operating EBITA margin improvement from 18.4% to 21.4%.
- The diagnostic business also saw a revenue increase to INR372 crore, with operating EBITA margins improving to 21.5% from 17.2% in the previous year.
- Hospital occupancy improved to 72%, translating into a 5.8% increase in occupied beds, driven by growth in key specialties like oncology and neurosciences.
- The company is making significant progress in digitalization, with digital revenue contributing 29.3% to overall hospital revenue, up from 25.6% in the previous year.
- Despite improvements, the diagnostic business growth remains a challenge, with only a 3.4% increase in revenue year-over-year.
- Legal costs have been higher this year due to more hearings, impacting overall profitability.
- Some hospitals are still operating below 10% EBITA margins, with challenges in improving performance in certain facilities.
- The company is facing seasonal impacts on hospital occupancy, which may affect short-term profitability.
- The acquisition of a 31.52% stake in Agilus Diagnostics from PE investors will increase debt, potentially impacting the balance sheet.
Ladies and gentlemen, good day. And welcome to the Q2 FY 25 post results conference call of, Fortis Healthcare Limited.
As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call? Please signal an operator by pressing * and 0 on your Touchstone phone. Please note that this conference is being recorded.
And now hand the conference over to Mr Anurag Kalra, Senior Vice President investor relations at part of Forest Health Care Limited. Thank you and over to you, sir.
Thank you, Nirav. Very good evening, ladies and gentlemen, and thank you for taking the time to join us on one of Q2 FY25 earnings call. We realize it's a bit late, so we do really appreciate you joining us for the call. The call is chaired by Dr Ashutosh Raghuvanshi and our CEO and managing director. With him, we have Mr Vivek Kumar Goyal,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
